Meeder Advisory Services Inc. Invests $998,000 in Medpace Holdings, Inc. $MEDP

Meeder Advisory Services Inc. acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,884 shares of the company's stock, valued at approximately $998,000.

Several other hedge funds also recently bought and sold shares of MEDP. BlackRock Inc. acquired a new position in shares of Medpace in the 2nd quarter worth approximately $1,323,047,000. AQR Capital Management LLC increased its holdings in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock valued at $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company's stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Franklin Resources Inc. raised its position in Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company's stock valued at $168,198,000 after purchasing an additional 183,645 shares during the period. Finally, Norges Bank purchased a new stake in Medpace in the fourth quarter valued at approximately $102,156,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insider Buying and Selling

In other news, Director Cornelius P. Mccarthy III sold 1,140 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the transaction, the director directly owned 12,275 shares of the company's stock, valued at approximately $7,430,916.75. The trade was a 8.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the business's stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares of the company's stock, valued at approximately $37,790,400. This represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 67,195 shares of company stock worth $37,989,998. 20.50% of the stock is owned by corporate insiders.

Medpace Trading Up 3.0%

Medpace stock opened at $608.27 on Thursday. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The stock's fifty day simple moving average is $544.34 and its 200-day simple moving average is $491.59. The firm has a market capitalization of $16.98 billion, a P/E ratio of 35.65, a P/E/G ratio of 2.63 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. During the same period last year, the firm earned $3.10 earnings per share. The company's revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analysts Set New Price Targets

MEDP has been the subject of several research analyst reports. Royal Bank Of Canada raised their price target on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Truist Financial boosted their price objective on Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a report on Friday, July 24th. Barclays set a $600.00 target price on Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Finally, TD Cowen increased their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, Medpace currently has an average rating of "Hold" and a consensus target price of $584.18.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source